References
1. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology2000;118: 1117–23
2. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol2015, 8(1):1-9
3. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol.2013;10: 666-75
4. Ballweber E, Hannappel E, Huff T, Stephan H, Haener M, Taschner N, Stoffler D, Aebi U, Mannherz HG. Polymerization of chemically cross-linked actin:thymosin beta(4) complex to filamentous actin: alteration in helical parameters and visualization of thymosin beta(4) binding on F-actin.J Mol Biol 2002;315:613-25
5. Gupta S, Kumar S, Sopko N, Qin Y, Wei C, Kim IK. Thymosin β4 and cardiac protection: implication in inflammation and fibrosis. Ann N Y Acad Sci2012,1269:84-91
6. Qiu P,Wheater MK,Qiu Y, Sosne G..Thymosin beta4 inhibits TNF-alpha -induced NF-kappaB activation, IL-8 expression, and the sensitizing effects by its partners PINCH-1 and ILK. FASEB J2011;25:1815-1826
7. Dong QY,Han T,Wang LF,Dong YP, Liu Y,Wang B.The significance of serum thymosin β4 levels in patients with non-alcoholic fatty liver disease[J].Tianjin Medical Journal2013; 41:97-100
8. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratziu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53
9. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with no-nalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-8
10. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, Chim AM, Yeung DK, Chan FK, Woo J, Yu J, Chu WC, Wong VW. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012;56:1363-70.
11. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology2010; 51: 111-20
12. Adams LA, Talwalkar JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006; 40 Suppl 1: S34-S38
13. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, KatoS, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y,Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, MaeyamaS, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis(NASH) and also of the severity of fbrosis in NASH. J Gas-troenterol 2007; 42: 573-82
14. Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroen-terol 2010; 16: 4784-91
15. Maleki I, Rastgar A, Hosseini V, Taghvaei T, Rafei A, Barzin M, Torabizadeh Z, Naghshvar F, Khalilian A. High sensitive CRP and pentraxine 3 as noninvasive biomarkers of nonalcoholic fatty liver disease. Eur Rev for Med Pharmacol Sci 2014; 18: 1583-90
16. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014; 20(24): 7718-29
17. Rafq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol 2009; 7: 234-8
18. Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, Abolghasemi H, Amini S, Maghsoudlu M, Deyhim MR, Rezvan H, Pourshams A. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes.World J Gastroenterol 2008; 14: 2867-71
19. Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47:239-4
20. Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, Sung JJ. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005;21: 407-13
21. Leite NC, Salles GF, Araujo AL, VillelaNogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type2 diabetes mellitus. Liver Int 2009; 29:113-9
22. Tian YY,Wang YB,Tan LL,Wang YY,Chen Y. value of Tβ4 liver function of non-alcoholic liver disease. Chin Gastroenterol Hepatol2014;23:432-4
23. Day CP, James OF. Steatohepatitis: a tale of two“hits”? Gastroenterology1998; 114: 842-5
24. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695-708
25. Ishikawa H, Takaki A, Tsuzaki R, Yasunaka T, Koike K, Shimomura Y, Seki H, Matsushita H, Miyake Y, Ikeda F, Shiraha H, Nouso K,Yamamoto K. L-Carnitine Prevents Progression of Non-Alcoholic Steatohepatitis in a Mouse Model with Upregulation of Mitochondrial Pathway. PLoS One. 2014, 9: e100627
26. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med2010:1603-16